Compare GSK plc (GSK) vs Intel Corp (INTC) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Intel (INTC) trades at $107.76, up 4.5% on the day, with a bearish technical signal but strong recent earnings beats. The company reported a net loss of -$267M for 2025, resulting in negative profit margins and ROE, while valuation ratios like a P/E of 904 appear extremely elevated. Positive sentiment is driven by news of progress with ASML's next-generation chipmaking technology and Jim Cramer's endorsement, with earnings due July 23.

The outlook is mixed: strategic manufacturing progress and AI ambitions offer long-term opportunity, but near-term fundamentals are weak with negative profitability. Key risks include intense semiconductor competition and execution on the capital-intensive foundry transition. Analyst consensus is a 'Hold' with a $107.55 price target, indicating the stock is fairly valued at current levels.